Fate Therapeutics Inc
NASDAQ:FATE

Watchlist Manager
Fate Therapeutics Inc Logo
Fate Therapeutics Inc
NASDAQ:FATE
Watchlist
Price: 1.19 USD 13.33% Market Closed
Market Cap: 137.3m USD

Operating Margin

-2 448.2%
Current
Declining
by 1 180.9%
vs 3-y average of -1 267.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 448.2%
=
Operating Income
$-174.7m
/
Revenue
$7.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 448.2%
=
Operating Income
$-174.7m
/
Revenue
$7.1m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Fate Therapeutics Inc
NASDAQ:FATE
137.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 11 913 companies
5th percentile
-2 448.2%
Low
-3 291 400% — 1.3%
Typical Range
1.3% — 16.8%
High
16.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -3 291 400%
30th Percentile 1.3%
Median 8.6%
70th Percentile 16.8%
Max 1 032 600%

Fate Therapeutics Inc
Glance View

Market Cap
137.3m USD
Industry
Biotechnology

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 449 full-time employees. The company went IPO on 2013-10-01. The firm is focused on the development of programmed cellular immunotherapies for patients with cancer. The company uses human induced pluripotent stem cells (iPSCs) generated from its proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The firm is advancing a pipeline of programmed cellular immunotherapies, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master iPSC lines for the treatment of cancer. The firm's product pipeline includes FT596, FT538, FT576, FT536, FT573, FT819, FT500 and FT516. FT516 is an investigational off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a novel CD16 (hnCD16) Fc receptor. FT596 is an investigational off-the-shelf CAR NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.

FATE Intrinsic Value
0.46 USD
Overvaluation 61%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-2 448.2%
=
Operating Income
$-174.7m
/
Revenue
$7.1m
What is Fate Therapeutics Inc's current Operating Margin?

The current Operating Margin for Fate Therapeutics Inc is -2 448.2%, which is below its 3-year median of -1 267.4%.

How has Operating Margin changed over time?

Over the last 3 years, Fate Therapeutics Inc’s Operating Margin has decreased from -454.1% to -2 448.2%. During this period, it reached a low of -3 291.5% on Mar 31, 2024 and a high of -191.8% on Mar 31, 2023.

Back to Top